79. Dr. Scott Sherr: Hyperbaric Therapy: This is How Pressure + Oxygen Unlock Healing

Low energy, brain fog, and poor recovery aren't just part of getting older—they're often signs that your cells are underperforming. And one major reason? They're starved for oxygen. In this episode of Extend, I talk with Dr. Scott Sherr, a hyperbaric medicine specialist who helps patients and doctors worldwide use oxygen therapy to restore cellular health. We get into what hyperbaric oxygen therapy (HBOT) actually does—not just more oxygen, but how it shifts gene expression, activates stem cells, and supports mitochondrial repair. We also discuss who shouldn't jump into HBOT too soon, and why testing antioxidant capacity and metabolic function is essential before starting. This isn't a quick fix—it's a targeted tool that works when your system is ready. If you're dealing with lingering symptoms or want to stay sharp and resilient long-term, this episode gives you a clear understanding of how HBOT fits into a true healthspan strategy. Dr. Scott Sherr is a board-certified internist and global expert in hyperbaric oxygen therapy, with over 20 years of clinical experience. He helps patients and physicians use HBOT to improve recovery, brain health, and long-term cellular function. We Also Discuss: The Real Goal: Longevity and Feeling Amazing Why Most Longevity Advice Misses the Mark Oxygen as Medicine? Inside Hyperbaric Therapy What Actually Happens in a Hyperbaric Chamber Can Oxygen Reverse Inflammation and Fatigue? Using Hyperbaric for Energy, Focus, and Recovery Thank You to Our Sponsor: IM8: Try IM8 today with a 30-day money back guarantee. You can get 20% off your first order with code DRSHAH at https://im8health.com/discount/DRSHAH. Learn more about Dr. Shah: Website: https://www.drshah.com/ Clinic: https://www.next-health.com/ Instagram: https://www.instagram.com/darshanshahmd/   Learn more about Dr. Scott Sherr: Website: https://www.hyperbaricmedicalsolutions.com Instagram: https://www.instagram.com/drscottsherr/  

There are no comments yet.

Please log in to write the first comment.